Effective March 2, 2017, Regeneron Pharmaceuticals, Inc. appointed Christopher Fenimore as Vice President, Controller. As previously reported, the Company's current controller, Douglas S. McCorkle, is retiring; Mr. McCorkle's retirement will be effective February 10, 2017. From the effective date of Mr. McCorkle's retirement until the effective date of Mr. Fenimore's appointment, the function of the company's principal accounting officer will be assumed by Robert E. Landry, Senior Vice President, Finance and Chief Financial Officer. Mr. Fenimore will become the Company's principal accounting officer on the effective date of his appointment. Mr. Fenimore, 46, has served as Vice President, Deputy Controller since January 2017 and previously served as Vice President, Financial Planning from December 2003 to December 2016. On January 27, 2017, the board of directors of the company elected N. Anthony Coles, M.D. as a Class II director. Dr. Coles has also been appointed to serve on the Audit Committee of the Board.